Literature DB >> 19121871

Depression is an early disease manifestation in lupus-prone MRL/lpr mice.

Hua-Xin Gao1, Sean R Campbell, Min-Hui Cui, Pu Zong, Jong Hee-Hwang, Maria Gulinello, Chaim Putterman.   

Abstract

Many lupus patients develop neuropsychiatric manifestations, including cognitive dysfunction, depression, and anxiety. However, it is not clear if neuropsychiatric lupus is a primary disease manifestation, or is secondary to non-CNS disease. We found that MRL/lpr lupus-prone mice exhibited significant depression-like behavior already at 8 weeks of age, despite normal visual working memory, locomotor coordination and social preference. Moreover, depression was significantly correlated with titers of autoantibodies against DNA, NMDA receptors and cardiolipin. Our results indicate that lupus mice develop depression and CNS dysfunction very early in the course of disease, in the absence of substantial pathology involving other target organs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19121871      PMCID: PMC2675630          DOI: 10.1016/j.jneuroim.2008.11.009

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  64 in total

1.  "Subcortical" cognitive impairment in patients with systemic lupus erythematosus.

Authors:  E Leritz; J Brandt; M Minor; F Reis-Jensen; M Petri
Journal:  J Int Neuropsychol Soc       Date:  2000-11       Impact factor: 2.892

2.  The return of the frequency sweep: designing adiabatic pulses for contemporary NMR.

Authors:  M Garwood; L DelaBarre
Journal:  J Magn Reson       Date:  2001-12       Impact factor: 2.229

3.  A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus.

Authors:  L A DeGiorgio; K N Konstantinov; S C Lee; J A Hardin; B T Volpe; B Diamond
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

4.  Reduced olfactory performance in patients with major depression.

Authors:  B M Pause; A Miranda; R Göder; J B Aldenhoff; R Ferstl
Journal:  J Psychiatr Res       Date:  2001 Sep-Oct       Impact factor: 4.791

5.  beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program.

Authors:  R L Brey; R D Abbott; J D Curb; D S Sharp; G W Ross; C L Stallworth; S J Kittner
Journal:  Stroke       Date:  2001-08       Impact factor: 7.914

Review 6.  Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE).

Authors:  David Hermosillo-Romo; Robin L Brey
Journal:  Best Pract Res Clin Rheumatol       Date:  2002-04       Impact factor: 4.098

Review 7.  Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review.

Authors:  Philip B Gorelick
Journal:  Stroke       Date:  2002-03       Impact factor: 7.914

8.  Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer.

Authors:  Y Shoenfeld; A Nahum; A D Korczyn; M Dano; R Rabinowitz; O Beilin; C G Pick; L Leider-Trejo; L Kalashnikova; M Blank; J Chapman
Journal:  Lupus       Date:  2003       Impact factor: 2.911

9.  Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus.

Authors:  H Fragoso-Loyo; Y Richaud-Patin; A Orozco-Narváez; L Dávila-Maldonado; Y Atisha-Fregoso; L Llorente; J Sánchez-Guerrero
Journal:  Arthritis Rheum       Date:  2007-04

Review 10.  Antigenic triggers and molecular targets for anti-double-stranded DNA antibodies.

Authors:  B Deocharan; X Qing; E Beger; C Putterman
Journal:  Lupus       Date:  2002       Impact factor: 2.911

View more
  32 in total

1.  Mechanisms of neuropsychiatric lupus: The relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier.

Authors:  Sivan Gelb; Ariel D Stock; Shira Anzi; Chaim Putterman; Ayal Ben-Zvi
Journal:  J Autoimmun       Date:  2018-04-04       Impact factor: 7.094

2.  All- Trans-Retinoic Acid Augments the Histopathological Outcome of Neuroinflammation and Neurodegeneration in Lupus-Prone MRL/lpr Mice.

Authors:  Michelle H Theus; Joshua B Sparks; Xiaofeng Liao; Jingjing Ren; Xin M Luo
Journal:  J Histochem Cytochem       Date:  2016-11-18       Impact factor: 2.479

3.  Immunology, autoimmunity, and autoantibodies in Parkinson's disease.

Authors:  Michal Benkler; Nancy Agmon-Levin; Sharon Hassin-Baer; Oren S Cohen; Oscar-Danilo Ortega-Hernandez; Amalia Levy; Samuel-Datum Moscavitch; Martine Szyper-Kravitz; Maya Damianovich; Miri Blank; Joab Chapman; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

4.  Tertiary lymphoid structures in the choroid plexus in neuropsychiatric lupus.

Authors:  Ariel D Stock; Evan Der; Sivan Gelb; Michelle Huang; Karen Weidenheim; Ayal Ben-Zvi; Chaim Putterman
Journal:  JCI Insight       Date:  2019-06-06

Review 5.  Neuropsychiatric lupus: new mechanistic insights and future treatment directions.

Authors:  Noa Schwartz; Ariel D Stock; Chaim Putterman
Journal:  Nat Rev Rheumatol       Date:  2019-03       Impact factor: 20.543

6.  Lipocalin-2 is a pathogenic determinant and biomarker of neuropsychiatric lupus.

Authors:  Elise V Mike; Hadijat M Makinde; Maria Gulinello; Kamala Vanarsa; Leal Herlitz; Gaurav Gadhvi; Deborah R Winter; Chandra Mohan; John G Hanly; C C Mok; Carla M Cuda; Chaim Putterman
Journal:  J Autoimmun       Date:  2018-08-30       Impact factor: 7.094

7.  CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus.

Authors:  Samantha A Chalmers; Jing Wen; Justine Shum; Jessica Doerner; Leal Herlitz; Chaim Putterman
Journal:  Clin Immunol       Date:  2016-08-26       Impact factor: 3.969

8.  Anti-DNA antibody mediated catalysis is isotype dependent.

Authors:  Yumin Xia; Ertan Eryilmaz; Qiuting Zhang; David Cowburn; Chaim Putterman
Journal:  Mol Immunol       Date:  2015-12-01       Impact factor: 4.407

Review 9.  Possible novel biomarkers of organ involvement in systemic lupus erythematosus.

Authors:  Dinglei Su; Rui Liu; Xia Li; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2014-03-06       Impact factor: 2.980

10.  Analysis of brain metabolites by gas chromatography-mass spectrometry reveals the risk-benefit concerns of prednisone in MRL/lpr lupus mice.

Authors:  Jia Zhou; Feilong Lu; Shan Li; Meijuan Xie; Haimei Lu; Zhijun Xie; Dehong Wu; Shuang Wang; Chengping Wen; Zheng-Hao Xu
Journal:  Inflammopharmacology       Date:  2019-11-30       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.